Editorial: Pediatric Pulmonary Hypertension

Maurice Beghetti1,2* and Frederic Lador2,3

1 Pediatric Cardiology Unit, Children's University Hospital, University of Geneva, Geneva, Switzerland, 2 Pulmonary Hypertension Program, University of Geneva, Geneva, Switzerland, 3 Division of Pneumology, University of Geneva, Geneva, Switzerland

Keywords: pediatrics, pulmonary circulation, pulmonary hypertension, diagnostic tests, routine, therapeutics

Pulmonary hypertension (PH) can present at any age from the neonatal period to adulthood. Pediatric PH is similar to adults but differentiates itself as in a growing child the lungs are still developing (1). It is a hemodynamic condition defined by an increased pulmonary artery mean pressure above or equal to 25 mmHg (1). This can be associated with multiple clinical conditions forming different etiological groups with specific and diverse pathological and pathobiological characteristics (1). When implying an abnormal reduction of small pulmonary arteries section due to endothelial dysfunction, medial proliferation, and adventitial fibrosis, the disease is called pulmonary arterial hypertension (PAH). PAH induces typically a severe and devastating PH that leads to right heart failure and premature death.

Until recently, the vast majority of studies published on PH were in the adult population but, as highlighted by the series of manuscript published in this issue of frontiers in pediatrics, awareness about pediatric PH is growing. In this line, a specific subgroup was dedicated to pediatrics at the last world symposium on PH with the publication of an excellent summary (1). Manuscripts not only on clinical research but also on basic science further highlight the interest in pediatric PH.

Epidemiologic data, mainly sourced from national and international registries, have recently been published, but the content of these registries varies depending on the center involved and the inclusion criteria (2). Indeed, most of the registries, including centers from developed countries, do not report children with PAH associated with HIV, in contrast to reports coming from developing countries (3). This may be due to the absence of this problem in developed countries in association with aggressive antiretroviral therapies or the absence of screening. L’Huillier et al. report the data from a Swiss cohort of patients with HIV (4). No patient presented with PH, but screening of PH was not systematically performed. This must be kept in mind when analyzing epidemiologic data.

In pediatrics, there is a need and a constant search for non-invasive assessments of PH, mainly because right heart catheterization, whenever it is still considered as the gold standard for hemodynamic evaluation and PH diagnosis is associated with potential risk in this particular population. So, the development of non-invasive tools for hemodynamic evaluation is not only desirable but mandatory in pediatrics. To this purpose, echocardiography gives invaluable information during the follow-up. Jone and Ivy did an excellent review of the current knowledge application of this approach in pediatric PH (5) and offer a basis for the remaining work dedicated to validation of most of the discussed parameters. Similarly, Day et al. reported their experience with the use of oxygen and sildenafil for assessment of pulmonary vascular reactivity in children (6). The response to vasoreactivity testing is crucial for orientation of treatment strategy as responders can be treated with calcium channel blockers with an excellent survival rate. This was clearly demonstrated in adults (7) but we still have to work to define a similar approach in children. Here, a major question still remains: what is the definition of a responder? The manuscript of Day et al. brings some more information with regards to vasoreactivity assessments in pediatric PH.
Still in the field of non-invasive assessment and potential markers of disease, Latus et al. reported their experience with the analysis of heart rate variability (HRV) showing that this parameter may be altered in pediatric patients with PH (8). HRV may indeed be related to disease severity and serve as an additional marker for PH evaluation.

Although there is still no cure for PAH, quality of life and survival have been improved significantly with specific drug therapies (9). Nevertheless, management of pediatric PAH remains challenging and depends mainly on results from adult clinical trials, a few specific pediatric studies and pediatric experts’ recommendations. Any additional report of the use of targeted therapies in children is of interest. Siehr et al. reported their experience with the use of sildenafil and concentrated on its potential side effects (10). One must remember that a question was raised on the use of sildenafil in children as the STARTS study reported an increased risk of death using high doses (11, 12). This led to a warning from the FDA and the approval of the medium dose by the European Medical Authorities. Even, if Siehr et al. reported no new side effects, they mention that the incidence of vascular, gastrointestinal, and neurologic side effects in pediatric patients on sildenafil therapy was 30%. Side effects were more common in patients on combination therapy with an endothelin receptor antagonist and/or a prostacyclin than in patients on sildenafil monotherapy.

Prior to the development of new therapeutic pathways, recognition of all pathobiological pathways involved in the development of pulmonary vascular disease are needed. Van loon et al. (13) reported their experience with erythropoietin (EPO) (10). In experimental PAH, EPO treatment restored the number of circulating endothelial progenitor cells (EPCs) to control level, improved pulmonary vascular remodeling, and showed important interplay with heme oxygenase (HO) activity. Inhibition of increased HO activity in PAH rats exacerbated progression of pulmonary vascular remodeling, despite the presence of restored number of circulating EPCs. It may be that both EPO-induced HO and EPCs are promising targets to improve the pulmonary vasculature in PAH.

Different specific issues related to pediatric PAH have been reported and highlight the need to continue active research in this field. It is of paramount importance to better understand the pathobiology of the disease, its behavior and discover new treatment pathway in order to finally curing this devastating disease.

**AUTHOR CONTRIBUTIONS**

MB wrote the editorial and reviewed most of the research topic manuscript. FL reviewed the content and added own ideas in the editorial; he also read all research topic manuscripts.

**REFERENCES**

1. Ivy DD, Abman SH, Barst RJ, Berger RM, Bonnet D, Fleming TR, et al. Pediatric pulmonary hypertension. *J Am Coll Cardiol* (2013) 62(25 Suppl):D117–26. doi:10.1016/j.jacc.2013.10.028

2. Berger RM, Beghetti M, Humpl T, Raskob GE, Ivy DD, Jing ZC, et al. Clinical features of paediatric pulmonary hypertension: a registry study. *Lancet* (2012) 379(9815):537–46. doi:10.1016/S0140-6736(11)61621-8

3. Wong AR, Rasool AH, Abidin NZ, Noor AR, Quah BS. Sildenafil as treatment for human immunodeficiency virus-related pulmonary hypertension in a child. *J Paediatr Child Health* (2006) 42(5):147–8. doi:10.1111/j.1440-1754.2006.00816.x

4. L’Huillier AG, Posfay-Barbe KM, Pietet H, Beghetti M. Pulmonary arterial hypertension among HIV-infected children: results of a national survey and review of the literature. *Front Pediatr* (2015) 3:25. doi:10.3389/fped.2015.00025

5. Jone PN, Ivy DD. Echocardiography in pediatric pulmonary hypertension. *Front Pediatr* (2014) 2:124. doi:10.3389/fped.2014.00124

6. Day RW. Comparison between the acute pulmonary vascular effects of oxygen with nitric oxide and sildenafil. *Front Pediatr* (2015) 3:16. doi:10.3389/fped.2015.00016

7. Sinbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. *Eur Respir J* (1998) 12(2):265–70. doi:10.1183/09031936.98.12020625

8. Latus H, Bandorski D, Rink F, Tiede H, Saploureas J, Ghofrani A, et al. Heart rate variability is related to disease severity in children and young adults with pulmonary hypertension. *Front Pediatr* (2015) 3:63. doi:10.3389/fped.2015.00063

9. Lador F, Sekarski N, Beghetti M. Treating pulmonary hypertension in pediatrics. *Expert Opin Pharmacother* (2015) 16(5):711–26. doi:10.1517/14656566.2015.1013937

10. Siehr SL, McCarthy EK, Ogawa MT, Feinstein JA. Reported sildenafil side effects in pediatric pulmonary hypertension patients. *Front Pediatr* (2015) 3:12. doi:10.3389/fped.2015.00012

11. Barst RJ, Beghetti M, Pulido T, Layton G, Konourina I, Zhang M, et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. *Circulation* (2014) 129(19):1914–23. doi:10.1161/CIRCULATIONAHA.113.05698

12. Beghetti M, Wacker Bou Puigdefabregas J, Merali S. Sildenafil for the treatment of pulmonary hypertension in children. *Expert Rev Cardiovasc Ther* (2014) 12(10):1157–84. doi:10.1586/14779072.2014.958077

13. Van Loon R, Bartelds B, Wagener F, Affara N, Mohaupt S, Winjburg H, et al. Erythropoietin attenuates pulmonary vascular remodeling in experimental pulmonary arterial hypertension through interplay between endothelial progenitor cells and heme oxygenase. *Front Pediatr* (2015) 3:71. doi:10.3389/fped.2015.00071

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2015 Beghetti and Lador. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.